DV
Dividend Vision

TRAX — First Tracks Biotherapeutics

First Tracks Biotherapeutics (TRAX)

Total return is 247.6% over the past 0.4 years, 232.3 points ahead of SPY at 15.3%.

First Tracks Biotherapeutics is an equity fund that tracks companies in the biotherapeutics sector. The fund has not yet commenced operations as of the provided data, with an inception date scheduled for March 2026, and currently lacks publicly available information on distribution frequency, yield characteristics, and expense ratio. Once launched, this fund may appeal to investors seeking exposure to the biopharmaceutical and therapeutic development industry.

TRAX key facts

Asset type
Stock
Asset class
Equity
Inception date
03/10/2026
Last close
$44.04
Market cap
$1,286,482,048
Average volume
446200.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.76